{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-25-032959","form_type":"8-K","ticker":"OVID","cik":"0001636651","company_name":"Ovid Therapeutics Inc.","filed_at":"2025-06-25T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.154059+00:00","generated_at":"2026-05-18T19:24:48.022235+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Ovid sells future ganaxolone royalties to Immedica for $7.0M cash","bullets":["Immedica pays $7.0M to acquire 100% of Ovid's royalty rights on ganaxolone sales outside China.","Ovid recorded ~$566K in ganaxolone royalty revenue in 2024; deal provides non-dilutive funding.","Immedica also obtains additional ganaxolone IP rights and assumes future IP costs.","Transaction expands Immedica's control of ganaxolone; no impact on Ovid's pipeline.","Amended license expected within six months to broaden field and territory."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-25-032959","json":"https://secwatch.observer/filing/0001628280-25-032959.json","markdown":"https://secwatch.observer/filing/0001628280-25-032959.md","text":"https://secwatch.observer/filing/0001628280-25-032959.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1636651/000162828025032959/0001628280-25-032959-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1636651/000162828025032959/ovid-20250625.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T19:24:48.022235+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}